Corvus touts early data on T cell lymphoma drug, makes PhIII plans

Corvus Phar­ma­ceu­ti­cals said that its T cell lym­phoma drug helped shrink tu­mors in pa­tients whose can­cer had re­lapsed, ac­cord­ing to an ear­ly cut of da­ta re­leased Thurs­day morn­ing.

Of 20 evalu­able pa­tients, three had com­plete re­spons­es, and three had par­tial re­spons­es as of May 18. One pa­tient with a com­plete re­sponse and two with par­tial re­spons­es are still on Corvus’ drug, which is an ITK in­hibitor.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN